 | |
| Clinical data | |
|---|---|
| Other names | 4-Ethylthio-2,5-dimethoxy-α-ethylphenethylamine |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H23NO2S |
| Molar mass | 269.40 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
4C-T-2, also known as 2,5-dimethoxy-4-ethylthio-α-ethylphenethylamine, is a synthetic drug of the phenethylamine, phenylisobutylamine, and 4C families.[1][2][3] It is the α-ethylated analogue of 2C-T-2.[1][2][3]
Pharmacology
[edit]Pharmacodynamics
[edit]| Target | Affinity (Ki, nM) |
|---|---|
| 5-HT1A | 5,339 |
| 5-HT1B | >10,000 |
| 5-HT1D | >10,000 |
| 5-HT1E | 9,879 |
| 5-HT1F | ND |
| 5-HT2A | 274 (Ki) 13.1–53 (EC50Tooltip half-maximal effective concentration) 78% (EmaxTooltip maximal efficacy) |
| 5-HT2B | 58.1 (Ki) 630 (EC50) ND (Emax) |
| 5-HT2C | 469 (Ki) 7.3–13.2 (EC50) 86–121% (Emax) |
| 5-HT3 | >10,000 |
| 5-HT4 | ND |
| 5-HT5A | 1,587 |
| 5-HT6 | >10,000 |
| 5-HT7 | 3,829 |
| α1A, α1B | >10,000 |
| α1D | ND |
| α2A–α2C | >10,000 |
| β1 | >10,000 |
| β2 | 124.9 |
| β3 | ND |
| D1, D2 | >10,000 |
| D3 | 1,273 |
| D4, D5 | >10,000 |
| H1–H4 | >10,000 |
| M1–M5 | >10,000 |
| I1 | 946.5 |
| σ1 | 514.6 |
| σ2 | >10,000 |
| TAAR1Tooltip Trace amine-associated receptor 1 | ND |
| SERTTooltip Serotonin transporter | >10,000 (Ki) |
| NETTooltip Norepinephrine transporter | >10,000 (Ki) |
| DATTooltip Dopamine transporter | >10,000 (Ki) |
| MAO-ATooltip Monoamine oxidase A | 11,800 (IC50Tooltip half-maximal inhibitory concentration) |
| MAO-BTooltip Monoamine oxidase B | >100,000 (IC50) |
| Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [4][5][2][3][6] | |
4C-T-2 acts as a serotonin 5-HT2 receptor agonist, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.[2][3]
History
[edit]4C-T-2 was first described in the scientific literature by at least 2005.[6] It was more fully characterized in 2010[2] and then in 2023.[3]
See also
[edit]References
[edit]- 1 2 Shulgin A, Manning T, Daley P (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley: Transform Press. ISBN 978-0-9630096-3-0. Retrieved 2 November 2024.
- 1 2 3 4 5 Ray TS (February 2010). "Psychedelics and the human receptorome". PLOS ONE. 5 (2) e9019. Bibcode:2010PLoSO...5.9019R. doi:10.1371/journal.pone.0009019. PMC 2814854. PMID 20126400.
- 1 2 3 4 5 Cunningham MJ, Bock HA, Serrano IC, Bechand B, Vidyadhara DJ, Bonniwell EM, et al. (January 2023). "Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs". ACS Chemical Neuroscience. 14 (1): 119–135. doi:10.1021/acschemneuro.2c00597. PMC 10147382. PMID 36521179.
Table S2. 5-HT2A and 5-HT2B IP1 agonism assay summary (EC50 values, duplicate averages only), performed at Cerep, Eurofins France [...]
- ↑ "Kᵢ Database". PDSP. 1 April 2025. Retrieved 1 April 2025.
- ↑ Liu T. "BindingDB BDBM50164331 1-(4-Ethylsulfanyl-2,5-dimethoxy-benzyl)-propylamine::CHEMBL372719". BindingDB. Retrieved 1 April 2025.
- 1 2 Gallardo-Godoy A, Fierro A, McLean TH, Castillo M, Cassels BK, Reyes-Parada M, et al. (April 2005). "Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling". Journal of Medicinal Chemistry. 48 (7): 2407–2419. doi:10.1021/jm0493109. PMID.